Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia

被引:10
作者
Bouali, Y
Gaillard-Kelly, M
Marie, PJ
机构
[1] Hoechst Marion Roussel, Aventis Pharma, F-93235 Romainville, France
[2] Hop Lariboisiere, Ctr Viggo Petersen, F-75475 Paris, France
关键词
trimegestone; estradiol; norethisterone; bone turnover; osteopenia; osteoporosis;
D O I
10.1080/01629778300000451
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of trimegestone (1 mg/kg/day orally), a novel norpregnane progestin, and 17 beta -estradiol (10 mug/kg/day subcutaneously), alone and in combination, on bone mass and turnover were investigated using an experimental model of osteoporosis involving ovariectomized rats. An equivalent dose (1 mg/kg/day orally) or norethisterone was used as a reference progestin. Six-month-old vats were ovariectomized and left untreated for 2 months to allow the development of osteopenia. Treatment With a progestin, alone or in combination with estradiol, was then started and continued for 2 months. Bone was assessed by a combination of static and dynamic histomorphometric measurement ltr, by densitometry and by the use of biochemical markers of bone turnover. Ovariectomy induced a pronounced uterine atrophy, which was reversed by estradiol. Trimegestone effectively counteracted the uterotropic effect of estradiol, whilst norethisterone showed a less pronounced antagonistic effect. A severe osteopenia was established in the initial 2 months after ovariectomy, and further bone loss occurred during the 2-month treatment period in animals not receiving estradiol. This effect was associated with a marked increase in both biochemical and dynamic histomorphometric markers of bone turnover, reflecting in an imbalance between resorption and formation. 17 beta -estradiol given alone prevented further bone loss, but neither trimegestone nor norethisterone alone had a beneficial effect on bone mass and turnover. When given in combination with 17 beta -estradiol, however, trimegestone significantly improved its effect on bone mass and turnover. This effect was more potent than that induced by combined 17 beta -estradiol and norethisterone therapy. We conclude that trimegestone, when combined with 17 beta -estradiol, is a more effective progestin than norethisterone in preventing bone loss in adult ovariectomized rats.
引用
收藏
页码:48 / 55
页数:8
相关论文
共 21 条
[1]  
BARENGOLTS EI, 1991, CELLS MAT S1, V1, P105
[2]  
BARENGOLTS EI, 1990, BONE, V10, P113
[3]  
Baron R.A., 1983, BONE HISTOMORPHOMETR, P13
[4]   ESTROGEN REPLACEMENT THERAPY AND FRACTURES IN OLDER WOMEN [J].
CAULEY, JA ;
SEELEY, DG ;
ENSRUD, K ;
ETTINGER, B ;
BLACK, D ;
CUMMINGS, SR .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (01) :9-16
[5]  
GAMBRELL RD, 1989, INT J FERTIL, V34, P315
[6]  
HIETALA EI, 1990, BONE MINER, V20, P57
[7]   A COMPARATIVE-STUDY OF THE ACTIONS OF TAMOXIFEN, ESTROGEN AND PROGESTERONE IN THE OVARIECTOMIZED RAT [J].
KALU, DN ;
SALERNO, E ;
LIU, CC ;
ECHON, R ;
RAY, M ;
GARZAZAPTA, M ;
HOLLIS, BW .
BONE AND MINERAL, 1991, 15 (02) :109-123
[8]   EVALUATION OF THE PATHOGENESIS OF SKELETAL CHANGES IN OVARIECTOMIZED RATS [J].
KALU, DN ;
HARDIN, RR ;
COCKERHAM, R .
ENDOCRINOLOGY, 1984, 115 (02) :507-512
[9]   BENEFITS AND RISKS OF ESTROGEN REPLACEMENT THERAPY [J].
LOBO, RA .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 173 (03) :982-989
[10]   FRACTURE PROTECTION PROVIDED BY LONG-TERM ESTROGEN-TREATMENT [J].
MAXIM, P ;
ETTINGER, B ;
SPITALNY, GM .
OSTEOPOROSIS INTERNATIONAL, 1995, 5 (01) :23-29